<DOC>
	<DOC>NCT01464099</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.</brief_summary>
	<brief_title>Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Subjects with type 1 diabetes treated with insulin for at least 12 months BMI (Body Mass Index) between 18.029.0 kg/m^2 Negative fasting Cpeptide (below or equal to 0.6 ng/mL) HbA1c (glycosylated haemoglobin A1c) below or equal to 10.0% Current treatment with insulin below or equal to 1.2 U/kg/day Subject should be in good health based on medical history, physical examination and routine laboratory data Any known/suspected allergies to trial medication or similar products/devices A subject who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator Clinically significant active disease of any kind Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator Blood donation (more than 500 mL) within the previous 9 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>